醫療科技評估 Health Technology Assessment
連結醫藥科技研究與政策決定的橋樑 is the systematic evaluation of properties, effects, and/or impacts of health technology

產業輔導

7. 藥物經濟學評估要如何執行?國內是否有相關規範或指引可參考? How are pharmacoeconomic evaluations carried out? Are there any local reference or guideline?

發佈日期:
點閱次數:683

        國際上,一般用於經濟評估研究品質之評估工具包括Drummond’s checklist、SIGN 50、BMJ Guidelines、Chiou’s check list等,但這些評估工具主要用於評估一般經濟評估研究,並未特別著重在「反映國情」上作評估,因此本中心參酌國際相關指引及品質評估工具,發展出適合於我國新醫療科技擬納入健保時的成本效益分析品質評估工具,該工具除了有一般國際上常用之品質評估項目外,另外多增加了評估反映國情的面向。此品質檢核表之前身為「國內實施藥物經濟學研究之品質評估報告」,該品質評估報告於民國101年經過實例試評、前健保局藥事小組討論修訂、召開廠商公開說明會交換意見、並徵詢國際著名的經濟評估專家意見後,於第9屆第18次藥事小組會議(民國101年9月6日)討論後,隨該次會議紀錄公布。若製藥產業界或研究機構想執行藥物經濟學評估,建議可參考此方法學指引,相關資料連結 http://nihta.cde.org.tw/Service/rule_more?id=8  。

 

Globally, tools used for assessing the quality of economic evaluation studies include Drummond’s checklist, SIGN 50, BMJ Guidelines and Chiou's checklist etc. However, these assessment tools are mainly used for assessing general economic evaluation studies, and not for assessing if the study fulfills local situation. Thus, the CDE has taken relevant guidelines and quality assessment tools of various countries into consideration, and developed a cost-effectiveness quality assessment tool suitable for Taiwan. In addition to quality assessment items used worldwide, the tool also contains an aspect assessing the study's representativeness of the local situation. The tool can be used in the pharmacoeconomic evaluations for new health technologies NHI listing. This quality checklist was previously known as the "Quality assessment report for locally implemented pharmacoeconomic evaluation studies". In 2012, after pre-test on actual studies, discussion and revision by experts, call for public opinions and consultation of international experts, the abovementioned quality assessment report was discussed at the 18th Meeting of the 9th Term Drug Benefit Committee held on Sep 6, 2012, and subsequently announced in the meeting minutes. If pharmaceutics or research institutes are keen to carry out local pharmacoeconomic evaluations, it is recommended to refer to the methodology guidelines in the following link  http://nihta.cde.org.tw/Service/rule_more?id=8.